Cognition Therapeutics
Clinical trials sponsored by Cognition Therapeutics, explained in plain language.
-
Experimental drug offered to lewy body dementia patients in expanded access program
Disease control NO_LONGER_AVAILABLEThis study provided the experimental drug CT1812 to people with mild-to-moderate dementia with Lewy bodies for up to one year. The program aimed to collect long-term safety information and see how well the drug worked in controlling disease symptoms. Participants took the drug da…
Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated Apr 04, 2026 06:50 UTC
-
New pill aims to protect the brain in Alzheimer's
Disease control OngoingThis study is testing whether a new daily pill called CT1812 can slow the progression of early Alzheimer's disease. About 540 people with early memory problems will take either the drug or a placebo for 18 months. Researchers will measure changes in memory, thinking skills, and d…
Phase: PHASE2 • Sponsor: Cognition Therapeutics • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC